The initiation of coverage by Scotiabank with a Sector Perform rating suggests that the analyst believes Biomarin Pharmaceutical's stock will perform in line with the sector average. The price target of $95 indicates where the analyst believes the stock price will move in the short term. This news is highly relevant to BMRN as it directly pertains to the company's stock and could influence investor decisions.